



## **X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo® (nivolumab)**

May 8, 2018

*Study designed to evaluate X4P-001-IO in expanded range of combination treatment settings to be presented at the Annual Meeting of the Association for Cancer Immunotherapy*

**Cambridge, MA – May 8, 2018** – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001-IO, the company's CXCR4 antagonist, has been selected for poster and oral presentation at the 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), taking place May 15-17 in Mainz, Germany. The presentations will describe clinical results from a pilot study of X4P-001-IO in combination with Opdivo® (nivolumab) in patients with clear cell renal cell carcinoma (ccRCC), expanding the range of combination treatment settings in which X4P-001-IO has been studied.

Details of the presentations on X4P-001 are as follows:

**Title:** The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy

**Author:** David F. McDermott, M.D., Beth Israel Deaconess Medical Center, Harvard Medical School

**Abstract #:** 77

**Poster Session:** Tumor Biology and Interaction with the Immune System, May 15<sup>th</sup>, 3:00 – 5:00 PM CET

**Oral Presentation Session:** Clinical Trials, May 17<sup>th</sup>, 11:45 AM – 1:00 PM CET

### **About X4P-001-IO in Cancer**

X4P-001-IO is an investigational selective, oral, small molecule antagonist of C-X-C receptor type 4 (CXCR4). CXCR4 is a chemokine receptor present in abundance on certain immune cells and cancer cells and it plays a critical role in immune cell trafficking, infiltration and activation in the tumor microenvironment. CXCR4 signaling is disrupted in a broad range of cancers, facilitating tumor growth by allowing cancer cells to evade immune detection and creating a pro-tumor microenvironment. X4P-001-IO has the ability to help restore immunity within the tumor microenvironment and has the potential to enhance the anti-tumor activity of approved and emerging oncology agents, such as checkpoint inhibitors and targeted therapies. X4P-001-IO is being investigated in several clinical studies in solid tumors.

### **About X4 Pharmaceuticals**

[X4 Pharmaceuticals](#) is developing novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. The Company's oral small molecule drug candidates antagonize the [CXCR4](#) pathway, which plays a central role in immune surveillance. X4's most advanced product candidate, X4P-001-RD, is in a Phase 2/3 study in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease. X4P-001-IO is currently under investigation in multiple clinical studies in solid tumors. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA. For more information, visit [x4.theyatesnetwork.com](http://x4.theyatesnetwork.com).

Opdivo® is a registered trademark of Bristol-Myers Squibb Company.

### **Media Contact:**

Kathryn Morris

Tel: 914-204-6412

[kathryn@theyatesnetwork.com](mailto:kathryn@theyatesnetwork.com)